BioTrends Research GroupPosted on:28 Jun 12 PharmiWeb.com (press release) In fact, interest in BG-12, along with Biogen Idec’s PEG-Avonex, Abbott / Biogen Idec’s daclizumab and Roche / Genentech’s ocrelizumab, has increased significantly compared to a year ago. While the greatest percentage of surveyed neurologists ... |
